Company intelligence / Profile preview
Novintum Bioscience
London, England, United Kingdomnovintumbioscience.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Novintum (as of 2018) was developing preclinical programs repurposing antibiotics to target mitochondrial metabolism in relapsed or treatment-resistant cancer; all programs appear to have been discontinued, and the company was dissolved in 2021
- Therapeutic areas
- Oncology
- Modalities
- AntibioticSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Novintum Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novintum Bioscience.